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Abstract
Transplantation of neural stems cells (NSCs) could be a useful means to deliver biologic therapeutics for late-stage
Alzheimer’s disease (AD). In this study, we conducted a small preclinical investigation of whether NSCs could be modified to
express metalloproteinase 9 (MMP9), a secreted protease reported to degrade aggregated Ab peptides that are the major
constituents of the senile plaques. Our findings illuminated three issues with using NSCs as delivery vehicles for this
particular application. First, transplanted NSCs generally failed to migrate to amyloid plaques, instead tending to colonize
white matter tracts. Second, the final destination of these cells was highly influenced by how they were delivered. We found
that our injection methods led to cells largely distributing to white matter tracts, which are anisotropic conduits for fluids
that facilitate rapid distribution within the CNS. Third, with regard to MMP9 as a therapeutic to remove senile plaques, we
observed high concentrations of endogenous metalloproteinases around amyloid plaques in the mouse models used for
these preclinical tests with no evidence that the NSC-delivered enzymes elevated these activities or had any impact.
Interestingly, MMP9-expressing NSCs formed substantially larger grafts. Overall, we observed long-term survival of NSCs in
the brains of mice with high amyloid burden. Therefore, we conclude that such cells may have potential in therapeutic
applications in AD but improved targeting of these cells to disease-specific lesions may be required to enhance efficacy.
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Introduction
The extracellular deposition of the amyloid beta peptide (Ab)i s
a requisite pathology for diagnosis of Alzheimer’s disease (AD)
[1,2]. Ab peptides also form dimers and oligomers that may play a
role in inducing the neurodegeneration underlying AD-associated
emotional, learning, and memory deficits [3]. Currently there are
no effective therapies for AD. For the past two decades, most of
the therapeutic focus on AD has been aimed at inhibiting or
eliminating amyloid pathology. The focus on amyloid derives from
genetic studies that have largely implicated amyloid deposition as a
possible trigger in initiating disease [4]. Recent failures of clinical
trials involving inhibitors of c-secretase, which is critical in the
generation of Ab40 and 42 [5], have cast doubt on the potential
efficacy of therapies targeting amyloid. Moreover, studies in mice
expressing mutant amyloid precursor protein (APP), via promoters
regulated by doxycycline, have demonstrated that cored Ab
plaques are highly stable structures that do not spontaneously
resolve [6]. Recently, Wang et al demonstrated that amyloid
plaque burden in this model can be partially ameliorated by
passive transfer of antibody to Ab peptide [7] suggesting that
additional interventions may promote clearance of amyloid
pathology. Current opinions on treatment of AD lean toward
early therapeutic interventions, including delivery of inhibitors of
c- and, or, b-secretase [4]. While these approaches hold promise if
issues of toxicity can be overcome, they offer little hope for patients
with fulminant, late-stage disease.
The discovery of NSCs in the adult [8] and the development of
ex vivo protocols to culture and re-introduce these cells into the
central nervous system (CNS) [9,10] have led to significant interest
in using NSCs as possible vehicles for delivery of therapies for AD.
In theory, it should be possible to obtain NSCs from the brains of
patients with neurodegeneration, differentiate these NSCs to cell
types of interest in vitro, manipulate them to express therapeutic
biologics, and then re-introduce them to the patient’s brain. The
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by transplanting fibroblasts programmed to release nerve growth
factor (NGF) [11] and neprilysin, a protease that degrades Ab
peptides, into the brain [12]. Most recently, Blurton-Jones and
colleagues reported that NSCs transplanted into the hippocampus
of transgenic mice that express mutant amyloid precursor protein,
mutant presenilin 1, and mutant tau showed improved learning
and memory by stimulating release of brain derived neurotrophic
factor (BDNF) [13]. NSCs have also been reported to reduce
neural inflammatory responses in rats whose brains had been
injected with fibrillar forms of Ab42 [14]. Together, the results of
these studies support development of NSC-based therapies.
One of the major hurdles in developing NSC-based therapies is
delivery of the cells to the site or sites of injury. In instances of
acute brain pathology, endogenous and transplanted NSCs are
reported to show migratory potential [15–18]. In such settings,
stromal derived factor 1 (SDF1), angiopoietin 1 (Ang1) [16,19] and
other chemotactic factors are likely to diffuse from the injured area
and influence NSC migration [20]. In the case of AD, NSCs
modified to produce anti-amyloid biologics would be of greatest
benefit if they could be induced to migrate to sites of amyloid
deposition, or to distribute widely across the brain if they were
modified to produce secreted agents.
Metalloproteinase 9 (MMP9) is up-regulated specifically by
astrocytes reactive to Ab deposits and genetic deletion of this
protease in mice results in reduced catabolism of Ab [21].
Neprilysin, endothelin-converting enzyme and insulin degrading
enzyme are known to degrade Ab, but in side-by-side comparisons
with MMP9, only MMP9 degraded Ab fibrils in vitro and Ab
plaques in situ [22]. Thus, MMP9 would appear to have potential
to degrade pre-existing amyloid deposits.
In the present study, we sought to determine whether NSCs
could be modified to secrete MMP9, and then tested whether
transplanted NSCs expressing MMP9 could elevate levels of
MMPs in the brains of two established mouse models of
Alzheimer-type amyloidosis (APPswe/PS1dE9-Line 85 mice [23]
and the tet-APPsi model [6]). We found that levels of endogenous
MMPs were very high and that the enzyme delivered by NSCs
had no obvious impact on the levels of amyloid deposits in either
model. However, we did note that NSCs expressing MMP9
produced larger grafts; thus MMP9 may ultimately be a useful
reagent for enhancing survival or migration of transplanted NSCs.
Materials and Methods
Isolation of NSCs
NSCs from the subependymal zone were isolated as previously
described [10]. In brief, a rectangular forebrain block containing
the subventricular zone was isolated from neonatal (P3-P8) B6
mice. The olfactory bulb, cerebellum, hippocampus, lateral
portions of the striatum, and lateral and dorsal cerebral cortex
were removed. The remaining tissue was minced with a razor
blade, incubated in 0.25% trypsin/ethylenediaminetetraacetic
acid (EDTA, Atlanta Biologicals, Lawrenceville, GA) and
dissociated into a single cell suspension by triturating through a
diametrically descending series of pipettes. Cells were then pelleted
and washed several times before plating in NSC media. This
media comprised of DMEM/F12 (Invitrogen, Carlsbad, CA) with
16 N2 supplements (Invitrogen, Carlsbad, CA), 5% fetal bovine
serum, 100 U/mL penicillin, 100 mg/mL streptomycin, 35 mg/
mL Bovine Pituitary Extract (Sigma, Carlsbad, CA), and 250 ng/
mL amphotericin B (Fungizone; Invitrogen, Carlsbad, CA). NSC
monolayers in T25 culture flasks were maintained in media
supplemented with 20 ng epidermal growth factor (EGF) and
20 ng fibroblast growth factor (FGF; Sigma, St. Louis, MO) every
two to three days [10]. Immediately prior to transplantation,
monolayers were detached from culture flasks with 0.25% trypsin
(Invitrogen, Carlsbad, CA), pelleted (10006g for 5 min), washed
twice with 200 mlo f1 6 Dulbecco’s Phosphate Buffered Saline
(dPBS) and diluted to approximately 5610
4 cells/mli n1 6dPBS.
Two reference cell counts were performed on a hemacytometer to
determine cell concentration.
Animals
Experiments were performed on adult APPswe/PS1dE9 Line
85 mice, CamKII-tTa/tetAPPswe/ind (tetAPPsi) mice, and non-
transgenic mice using protocols and procedures approved by the
University of Florida Institutional Animal Care and Use
Committee (Protocol #200801921). Line 85 mice constitutively
overexpress chimeric mouse/human APP695 harboring the
Swedish K670M/N671L mutations (Mo/HuAPPswe) and human
PS1with the exon-9 deletion mutation (PS1dE9) [23]. In tet/APPsi
mice, expression of APP can be suppressed by adding doxycycline,
a tetracycline analog to the mouse chow [6]. These mice were
raised without doxycycline to 10 months of age allowing plaque
deposition to occur. Approximately two weeks prior to experi-
mentation, a doxycycline diet was initiated to halt APP
production. Both host mice and NSC donor mice were congenic
on the C57BL/6J background, eliminating any problems with
graft rejection.
Surgical Procedures and Cell Transplantation
Mice were deeply anesthetized with 1–5% isoflurane. The top
of the head was shaved and sterilized with alternating swipes of
betadine antiseptic and 70% ethanol. The mice were securely
mounted with ear bars and a nose bar to a stereotaxic apparatus
(Kopf Instruments, Tujunga, CA). The anesthesia mixture was
delivered through an inlet within the nose bar enclosure for the
duration of the surgery. A sterile scalpel was used to make a small
incision into the skin above the skull. The skin was reflected in
order to expose Bregma and a hole was drilled to allow cells to be
injected as described below. Following injection, the needle was
left in place for 3 minutes to minimize backflow before being
slowly withdrawn. The incision was closed with staples and mice
were allowed to recover in a 37uC chamber.
In general, most of the infusion parameters used here are
established protocols in other studies [18,24,25]. Cell numbers and
volumes used here are similar to those used in intracranial
surgeries by Park and colleagues [24], in which mouse brains were
infused with 3610
5 NSCs in 8 mL. We took advantage of two
infusion systems depending on experimental needs. The first
system was an automated system for convection-enhanced delivery
(CED), calibrated with positive pressure to deliver NSCs at 1 mL/
min. CED results in nearly homogenous infusate concentration
[26] and minimizes artifacts that may come about due to infusion
pressure variability. Therefore, we used this system for short-term
cell distribution studies. The system consisted of a 100 mL gas-tight
syringe (Hamilton, Reno, NV) driven by a syringe pump (Cole-
Parmer, Vernon Hills, IL) connected to polyaryletheretherketone
(PEEK) tubing (ID=0.381 mm, OD=0.794 mm, length=0.5 m,
Upchurch Scientific, Oak Harbor, WA). The PEEK tubing was
coupled to a silica cannula (ID=50 mm, OD=147 mm, Polymicro
Technologies, Phoenix, AZ) via a microfluidic connector. We
typically harvested 4–6 confluent T75 flasks per experiment and
concentrated the cells at 5610
4 cells/mL in order to reliably have
enough volume for transplantation and for void volume.
The second system we used was a Hamilton 33 gauge 10 mL
syringe (Hamilton Company, Reno, NV). This system required
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to concentrate similar yields of NSCs into 1610
5 cells/mL and
therefore infuse almost half as much volume in studies on the
therapeutic potential of NSCs. Smaller volumes in these studies
minimized risk of infusion-related damage to host tissue in long-
term experiments. 0.25 mL was infused every 15 seconds.
In studies of NSC distribution, a single bolus of NSCs was
infused into 8–14 month non-transgenic mice. We targeted NSCs
to various brain subcompartments with coordinates away from
Bregma in the anterior/posterior (AP), medial/lateral (ML), and
dorsal/ventral (DV) planes. Cells were deposited bilaterally with
coordinates targeting the fimbria (AP: 20.2 mm, ML: +/
21.2 mm, DV: 22.5 mm from the dura), thalamus (AP:
22.0 mm, ML: +/21.5 mm, DV: 24 mm from the skull),
striatum (AP: +1.18 mm, ML: +/21.5 mm, DV: 24 mm from
the skull) and hippocampus (AP: 22.00 mm, ML: +/22.0 mm,
DV:21.5 mm, 22.1 mm, and 22.8 mm from the skull). Hippo-
campal DV coordinates correspond to the superior aspect,
dorsoventral center, and inferior aspect of the septal hippocampus,
respectively. ,5610
5 cells (9.8 mL) were infused into each site of
the thalamus, striatum and hippocampus; ,1610
5 NSCs
(1.96 mL) were infused into the fimbria to accommodate its
smaller spatial dimensions.
In studies that focused on modifying amyloid pathology, we
were interested in wide-spread distribution of NSCs in the
hippocampus of 13–14 month old transgenic APPswe/PS1dE9
mice or 9–10 month old transgenic tetAPPsi mice. We therefore
manually infused NSCs at 3 sites with the following coordinates:
AP: +2 mm, ML: +/22 mm, DV: 2.0 mm, 22.3 mm, and
22.5 mm from the skull. ,1.25610
5 cells were deposited at
22.0 mm and 22.3 mm, while ,2.5610
5 cells were deposited at
22.5 mm for a total of ,5610
5 NSCs (4.9 mL). These coordinates
targeted hippocampal gray matter in regions ranging from CA3,
the molecular cell layer and the subgranular zone of the dentate
gyrus.
Vehicle-only infusions are frequently used as controls in
transplant studies. These are often performed on a parallel set of
age-matched animals. In our experience, aged-matched APPswe/
PS1dE9 mice have substantial variability in the amount of amyloid
deposited. We addressed this concern by performing a cell-free,
vehicle only, mock surgery in the equivalent area of the
contralateral hemisphere of animals receiving NSCs. This control
scheme allowed for direct comparison to each animals’ individual
amyloid burden while controlling for the immune response to
endogenous cells killed during needle penetration.
Preparation of Cells and Tissues for Analysis
To harvest tissues, mice were deeply anesthetized and
euthanized by isoflurane overdose followed by immediate
exsanguination and perfusion with cold 16 PBS. Whole brains
were quickly dissected out and placed in cold 4% paraformalde-
hyde fixative overnight. Fixed brains were immersed in 30%
sucrose before sectioning at 20 mm intervals within a cryostat.
Sections were stored in anti-freeze media at 220uC until further
processing. Cultures of NSC monolayers were similarly fixed and
stored. Fixed tissue sections and NSC monolayers were blocked
and permeabilized with 0.1% Triton-X, 10% goat serum in 16
PBS during immunochemical applications.
Immunochemistry
Primary antibodies used in this study include anti-Ab 6E10
(Signet, Dedham, MA), microglial antigen Iba1 (Wako, Rich-
mond, VA), astrocyte antigen GFAP (Dako Corporation, Carpin-
teria, CA), pan neuronal antigen BIII-Tubulin (Covance,
Princeton, NJ), anti-human MMP9 Clone 56-2A4 (Abcam,
Cambridge, MA), and anti-mouse MMP9 (courtesy of R. Senior,
Washington University). An antibody to copGFP (Evrogen,
Moscow, Russia) was used to detect GFP if fluorescence was too
low to detect directly. For both cultured cells and tissue sections,
Alexa 488 and Alexa 568 goat secondary antibodies (Invitrogen,
Carlsbad, CA) were used. Cell nuclei were stained with 49,6-
diamidino-2-phenylindole (DAPI, Invitrogen, Carlsbad, CA).
Antibodies as supplied by the manufacturer were diluted from
1:500 to 1:2000 for use in immunohistochemistry. Immunostained
cells and tissue sections were photographed with an Olympus
DP71 camera mounted on an Olympus BX60 microscope or an
Olympus DSU-IX81 Spinning Disc confocal microscope. Confo-
cal images were deblurred by a nearest neighbor algorithm.
Lentivirus Construction and Transduction
Self-inactivating Lentiviruses [27] were used to transduce NSCs
with expression cassettes for plankton copepod green fluorescent
protein (hereafter simply referred to as GFP; which is similar in
size to EGFP (26 kDA) but has more fluorescence output [28]).
Viral vectors were created using the pCDH cloning and expression
system (SBI, Mountain View, CA). The pCDH vector contained
cDNA for GFP under the elongation factor 1 (EF1) promoter.
Human MMP9 (2.54 kB) cDNA within a pCMV6-XL4 plasmid
vector (Origene, Rockville, MD) was cloned and then ligated into
the pCDH Lentiviral vector using Not1 restriction sites. The
Lentiviral vectors were packaged into Lentivirus pseudotyped with
vesicular stomatitis virus G (VSV-G) glycoprotein using a three
plasmid packaging system that included the pCDH construct (with
or without the MMP9 transgene) as previously described [29].
Final viral titers were approximately 1610
11 particles/mL.
Confluent cultures of NSCs were trypsinized and roughly 1610
5
cells were resuspended in 100 mL dPBS. These cells were
transduced by exposure to 6 mL of virus concentrate for 1.5 hrs
at 37uC, with agitation every 10–15 min. This ratio of virus to cells
was found to most optimally and consistently yield NSCs
expressing GFP. Transduced cells were grown to confluent
cultures in T25 flasks. Cells were trypsinized and resuspended in
5 mls of dPBS with 2% fetal bovine serum. GFP expressing cells
were then enriched by fluorescence activated cell sorting (FACS).
NSCs with GFP intensity below an arbitrary threshold value of 10
3
units were discarded. Cultures of remaining cells maintained high
GFP expression up to 6 months following FACS enrichment.
Real-time PCR was used to confirm conditioned media from
expanded cultures contained no viral genomic DNA (data not
shown) to ensure virus was not present in the injected NSCs cells.
Quantification of NSC Transplant Dimensions
To determine whether tetramethylammonium (TMA) distrib-
uted anisotropically or isotropically, Mazel et al. quantified
changes of TMA concentration along the orthogonal x, y and z
axes [30]. We adapted this method to perform analyses on infused
NSCs expressing GFP. An index of anisotropy, designated A, was
determined by the quotient of x/y, where x represents the distance
of engraftment on the transverse axis and y represents the vertical
axis.
A~(x=y)
By definition, an ideal ellipsoid would have a larger value of x
relative to y while a circle would have equal x and y values. In
practice, A values close to 1 represent isotropy while large A values
represent anisotropy. During sectioning, we punctured small holes
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infusions. For each infusion, one to two 20 mm sections containing
engraftments were analyzed with AxioVision LE software (Zeiss,
Jena, Germany). Images of samples with equal pixel/micrometer
value were used to determine the distance of x and y. An unpaired,
two-tailed Student’s t-test using Microsoft Excel was used to
compare A from different sites of infusion. A p-value of ,0.05 was
considered statistically significant.
To determine whether expression of MMP9 influenced the size
of the graft, we used Image Pro Plus software (MediaCybernetics,
Bethesda, MD). For this study, we focused on the area closest to
the site of injection from each animal, looking for sections with
evidence of needle track penetration. An unpaired, two-tailed
Student’s t-test using Microsoft Excel was used to compare values.
A p-value of ,0.05 was considered statistically significant.
Image Segmentation and 3D Reconstruction of NSC
Engraftments
A semi-automatic image segmentation routine was implemented
in MATLAB (MATLAB 2010a, The MathWorks, Inc., Natick,
Massachusetts USA) that distinguished regions of GFP expression
from control regions of the brain by means of a threshold unique
to each histological section. RGB images of the histological
sections were imported into MATLAB; however, only the green
channel of the images was used for image segmentation. The
average background signal was determined by averaging the signal
intensity in user-designated control regions of interest (GFP-free
regions of tissue) for each section. Similarly, the standard deviation
of noise was determined by evaluating the noise behavior in user-
designated noise regions of interest (tissue-free regions in images).
Thresholds were calculated by adding six times the standard
deviation of noise to the control signal intensity for each section.
The image segmentations were refined in ITK-SNAP [31], an
open source medical image segmentation tool. Refinements
included removing regions of auto-fluorescence (false-positives)
from the image segmentation as well as segmentation of
annotations such as scale bars. Three-dimensional reconstructions
were generated by first aligning the histological sections prior to
image segmentation and finally generating a mesh from the 3D
image segmentation using ITK-SNAP’s built in mesh generation
tool.
Semi-automated Analysis of Ab Plaque Number in
APPswe/PS1dE9 mice
Image Pro Plus software was used to quantify intensity over
background for images of 6E10 immunoreactive Ab plaques in
coronal sections as previously described [32]. Objects that were
,50 mm or had angular edges that did not correspond to Ab
plaques were excluded. Because transplanted cells largely settled in
the corpus callosum, we focused on a region of interest (ROI) that
included the dorsal hippocampus below the site of engraftment
and the cortex above the site of engraftment (1.25 mm62 mm).
To be consistent across mice, the vertical and horizontal boundary
of the ROI was the meeting of the dentate arms and the lateral
blade of the dentate gyrus, respectively (see Fig. S2 for an
example). For an internal control, analysis was performed on the
equivalent region of the contralateral hemisphere (non-infused
side). Ipsilateral versus contralateral plaque numbers were
analyzed using paired, two-tailed Student’s t-tests in Microsoft
Excel. Plaque numbers in animals receiving MMP9-NSCs and
GFP-NSCs were compared with an unpaired, two-tailed Student’s
t-test using Microsoft Excel. Similar analyses with NIH Image J
were performed on MMP9-NSC unilateral infusions into tetAPPsi
mice. However, in this cohort, a smaller ROI
(0.25 mm60.35 mm) was measured to better sample Ab plaque
burden in the immediate vicinity of engraftments; one edge of the
ROI was aligned with the engraftment and the number of Ab
plaques was compared with the equivalent region in the
contralateral hemisphere. A p-value of ,0.05 was considered
statistically significant.
Ab42 Degradation Assay
The method used to quantify the degradation of Ab42 has been
described previously [33]. Briefly, lyophilized Ab42 peptide
(rPeptide, Bogard, GA) was resuspended to 1 mg/mL in 1%
NH4OH and stored at 220uC according to manufacturer’s
directions. Stock preparations contained monomeric (4 kDa),
oligomeric (16 kDa, 20 kDa) and higher-order conformations
larger than 220 kDa [33]. 1610
5 NSCs were seeded and allowed
to grow within RS chambers (Nunc, Roskilde, Denmark) until
confluent. Cultures were rinsed and given Ab42 diluted in DMEM
at 4 mg/mL. The cells were allowed to internalize Ab42 from the
media for 3 hrs in 37uC. The cells were then rinsed and incubated
at 37uC with 1.5 mLs of culture media lacking Ab42. This media
and that of cells lysed immediately following rinsing were
collected, as were the conditioned media and lysate from wells
incubated for 3 hrs and 16 hrs. The lysis buffer based on NP40
(50 mM Tris, pH7.4, 250 mM NaCl, 5 mM EDTA, 50 mM NaF,
1m MN a 3V04, 1% nonidet P40 [NP40] FNN0021, Invitrogen,
Carlsbad, CA) was supplemented with 16 protease inhibitor
cocktail (Sigma, St. Louis, MO) and 1 mM PMSF. To determine
the fate of Ab42, we employed a sandwich-style ELISA
(Invitrogen, Carlsbad, CA) that is specific to full-length Ab42
(capture antibodies have opposing N- and C-terminal affinities).
ELISA readings of Ab42 content in lysate allowed for quantifi-
cation of NSC internalization and the subsequent loss of Ab42
from cell lysates was a measure of degradation. Readings from the
media assayed for the recycling of Ab42 back to the media. The
ELISA was processed with duplicates of each sample and
absorbance read at 450 nm using a spectrophotometer (Bio-Tek,
Winooski, VT). Data was normalized to culture plate wells that
were treated with Ab42, as described above, but contained no
cells. This control was performed because some of the peptide
adheres to the plastic plates non-specifically and is subsequently
released by buffers that are used to lyse cells or leaches into the
medium upon further incubation. The detection limit of the assay
was 10 pg/mL. An unpaired, two-tailed Student’s t-test using
Microsoft Excel was used to compare values. A p-value of ,0.05
was considered statistically significant.
In situ Metalloproteinase Gelatinase Activity
To detect metalloproteinase activity in situ, we followed a
protocol modified from Yan et al. [22]. Briefly, a 1% agarose
solution with 16 PBS and 0.1% Triton-X100 was made
homogeneous with three 10 sec pulses within a microwave oven
followed by brief vortexing. DQ gelatin (100 mg/mL, Invitrogen,
Carlsbad, CA) and DAPI (1:1000) were then added to the agarose
solution. A thin film of this mixture was quickly added to dry
sections mounted on glass slides and allowed to set overnight at
room temperature. Green fluorescence developed at sites where
metalloproteinase digestion of DQ gelatin occurred. This reaction
did not occur in sections from non-transgenic littermates and or
with addition of 0.8 mM of the general metalloproteinase inhibitor
1,10 Phenanthroline (PNTL; Sigma, St. Louis, MO).
Therapeutic Transplantation of NSCs
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Modification of NSCs to express MMP9
Multipotent NSCs were derived from the subventricular zone of
non-transgenic neonatal mice and cultured for multiple genera-
tions as we have previously described [10]. Self-inactivating
Lentiviruses [27] were used to generate NSCs expressing GFP
(GFP-NSCs) (Fig. 1A). Upon Lentiviral transduction, a subpop-
ulation of GFP-NSCs showed GFP fluorescence within three days
and remained fluorescent for up to six months. Fluorescence
Activated Cell Sorting (FACS) technology was used to enrich
undifferentiated GFP positive NSCs (Fig. 1B–G). These cells
formed expandable monolayers that were immunoreactive to BIII-
Tubulin, a pan neuronal marker recently associated with
subventricular zone neuronal precursor chains [10]; GFAP, an
astrocyte marker; and to a lesser extent, the microglial marker,
Iba1 (Fig. 1H–I; Fig. S1). BIII-Tubulin and GFAP are markers
previously associated with NSCs [10,34]. We have previously
shown that microglia are found in NSC cultures and are thought
to produce factors necessary for neurogenesis in NSC cultures
[35].
To develop NSCs as delivery vehicles for biologic therapeutics,
we tested whether these cells could be engineered to express
MMP9. For reasons delineated above, secreted MMP9 is an
excellent candidate biologic for enhancing the clearance of
amyloid deposits. Lentiviruses were thus constructed to co-express
human MMP9 and GFP for transduction of NSCs (Fig. 2A).
Following procedures similar to those outlined above, we enriched
for cells expressing high levels of GFP by FACS and ultimately
produced NSC cultures with a similar level of GFP expression as
control NSCs expressing only GFP (Fig. 2B and E). Immuno-
staining of these cultures with antibodies to MMP9 demonstrated
that only the cells transduced with MMP9 Lentiviruses expressed
the enzyme, which appeared to be located in the endoplasmic
reticulum (Fig. 2C, D compared to F, G; the strongest
immunoreactivity was concentrated around the nucleus). To
determine whether the enzyme was secreted, culture medium was
harvested from cells incubated for 7–14 days (Fig. 2H). The
enzyme was readily detected in culture medium with a relative
molecular mass of a size expected for the proenzyme. Together,
these studies demonstrate the relative ease with which NSCs can
be modified to express and secrete potentially therapeutic
molecules.
Distribution of Transplanted NSCs
NSCs expressing either MMP9 with GFP or GFP alone were
infused into the hippocampus of 13–14 month old APPswe/
PS1dE9 mice. Mice were subsequently harvested one month later
to assess the distribution of the transplanted cells. Despite evidence
of needle track penetration into the hippocampal gray mater
(Fig. 3A), the majority of engrafted cells were located in the
overlying corpus callosum (Fig. 3A–C, n.9 animals). A secondary
site of engraftment in 33% of the animals was the hippocampal
fissure (Fig. 3B). For our preclinical assessments, we also used the
tetAPPsi mouse model (see Methods). A similar distribution of
NSCs was observed in these mice (Fig. 3D). Thus, although the
intended target was the hippocampus, these NSCs tended to
colonize the overlying white matter tracts.
Figure 1. Ex vivo manipulation of NSCs. NSCs were transduced with Lentiviruses with GFP driven by the elongation factor 1 promoter (EF1) (A).
Transduction involved exposure of NSCs to virus concentrate for 1.5 hours with intermittent agitation. Following transduction, a population of more
fluorescent NSCs was observed by FACS analysis (B). Highly fluorescent cells defined by AU.10
3 (C) formed cultures with more uniform and robust
expression of GFP (D–G). Enriched NSCs formed expandable, long-term monolayers which expressed GFAP and BIII-Tubulin, markers commonly
associated with multipotent astrocytic stem cells (H–I). GFP fluorescence was detected directly in B–F and indirectly with an antibody specific to GFP
in G. The data are representative examples from three repeated isolations and transductions of NSCs.
doi:10.1371/journal.pone.0034097.g001
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deposition
For our first test of whether NSCs could deliver MMP9 to the
CNS at effective levels, MMP9-NSCs and NSCs expressing only
GFP were transplanted into the hippocampus of 13–14 month old
APPswe/PS1dE9 mice. Mice were subsequently harvested one
month later. With immunohistochemical stains for MMP9, we
were able to identify cells within the graft area that expressed
MMP9 (Fig. 4 A–C). However, immunoreactivity was not
confined to the area of the graft as cells adjacent to the NSCs,
marked by GFP expression, also immunostained for MMP9. It is
possible that there was cross-reactivity to endogenously expressed
MMP9. We note that very little MMP9 is normally expressed in
mouse brain, but what little mRNA that is expressed is present in
the white matter tracts of the corpus callosum (see Allen Brain
Atlas; www.mouse.brain-map.org). Thus, the immunoreactivity to
MMP9 antibodies that was seen adjacent to the grafts is likely to
be endogenous MMP9.
One of the most obvious effects of MMP9 expression was noted
by the size of the grafts formed by NSCs expressing MMP9;
MMP9-NSCs formed grafts that were 82.4% larger than grafts
formed by NSCs expressing only GFP (Fig. 5, p,0.01). Thus,
either more of the MMP9-NSCs survived injection or these cells
migrated further away from the injection site.
To determine whether transplantation had any effect on plaque
burden, we sampled the amount of Ab plaques around the
engraftments (see Fig. S2 for an example of how regions of interest
were outlined; ROI=1.25 mm62 mm). Because the rate of
amyloid deposition varies between animals, we focused our
comparison to plaque burden in the contralateral, mock-infused
hemisphere as an internal control. Additionally, we compared
animals that received MMP9-NSCs to animals receiving NSCs
that expressed only GFP. Most animals exhibited reductions in
plaque burden with some displaying notably strong effects (Fig. 6A,
C). In total, the amount of plaque reduction in all mice was a
modest 27% (Fig. 6B, n=9, p,0.01). Animals hosting MMP9-
NSCs had 28.6% less Ab plaques (n=5, p=0.03) and animals
hosting NSCs expressing only GFP had 26.4% less Ab plaques
(Fig. 6B; n=4, p=0.04). The difference in plaque reduction
between animals with NSCs engineered to overexpress MMP9
and animals with NSCs expressing only GFP was not statistically
significant. Thus, it appeared that transplantation of NSCs
lowered plaque numbers in the area proximal the graft. A similar
outcome was observed when we examined tetAPPsi mice (+
Doxycylcine) that had been unilaterally injected with NSCs
expressing MMP9 and allowed to survive for 2 months (Fig.
S3A–B). Compared to the same location in the contralateral side,
the area near NSC grafts on the injected side seemed to contain
less amyloid plaques (26% less, n=7). However, in a second set of
Figure 2. Expression and secretion of MMP9 in cultured NSCs. Cells were transduced with Lentiviruses that confer cytomegalovirus (CMV)
directed human MMP9 expression (A). MMP9 immunoreactivity was robustly detected in cells transduced with the MMP9 virus (B–D). Arrow indicates
MMP9 expressing cells with little detection in cells transduced with GFP only virus (E–G). Immunoblots of medium from cultured cells demonstrated
secretion of human MMP9 into the medium (H). Each lane contains 18 mL of conditioned medium from cells incubated for 7–14 days. Lane 1 was
loaded with 18 mL of a 1.3 mg/mL solution of purified human MMP9 proenzyme.
doi:10.1371/journal.pone.0034097.g002
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in one hemisphere and NSCs expressing only GFP in the
contralateral hemisphere to allow a direct side-by-side test of
MMP9 efficacy on pre-existing Ab plaques. Following a month of
engraftment, no obvious differences in plaque burden were
observed (see Fig. S3C for a representative example, n=9). We
therefore conclude that NSC-delivered MMP9 had no profound
therapeutic effect on plaque burden; though, as observed above,
the mere presence of NSCs produced a small but measurable
reduction in plaque numbers in regions of the brain proximal to
the graft.
Although we could find no evidence that MMP9 produced by
transplanted NSC cells could lower amyloid plaque burden, we
were intrigued by the observation that the area proximal to NSCs
seemed to have less amyloid plaques. This effect was noted in the
APPswe/PS1dE9 mice and in the tet-APPsi (+Doxycyline). This
observation suggested that NSCs might have some inherent ability
to lower Ab levels and slow the rate of amyloid deposition. Using
methodology we previously used to quantify microglial Ab42
catabolism [33], we determined that cultured NSCs internalized
and degraded Ab42 added to culture medium (Fig. S4A–B). Thus,
one possible explanation for the lower amyloid plaque burden
near NSC grafts could be due to increased catabolism of Ab
peptide that slows the rate of amyloid deposition. However, we
noted that the size of the graft showed no correlation with the
degree of amyloid plaque reduction (Fig. 6C). In general, the
larger grafts appeared to have more NSCs distributed over a wider
area and grafts formed by NSCs expressing MMP9 were
uniformly larger. Yet, there was no obvious correlation between
graft size and proximal amyloid plaque numbers. Thus, it is
Figure 3. Distribution of long-term NSC engraftments in APPswe/PS1dE9 mice. Symptomatic APPswe/PS1dE9 mice received NSCs at three
depths per infusion and were allowed to survive for one month. NSCs were mainly distributed in the corpus callosum despite evidence of needle
track penetration into the hippocampal gray matter (A; arrowheads indicate approximate position NSCs were released). In some instances, NSCs
formed secondary grafts in the hippocampal fissure (B; arrows). Closer inspection in NSCs engrafted in the corpus callosum of APPswe/PS1dE9 mice
(C) and tetAPPsi mice (D) revealed these cells had an elongated morphology characteristic of migrating cells; however, cells did not exit into the
cortex (CTX) or spread below CA1 neurons of the hippocampus (HIPPO). GFP expression was detected indirectly with an antibody specific to GFP in
all panels.
doi:10.1371/journal.pone.0034097.g003
Figure 4. In vivo expression of MMP9 by transplanted NSC cells. Confocal image of engraftment shows NSCs (arrows) and host cells
(arrowheads) were immunoreactive for MMP9 (A–C). The images shown are representative of an analysis of three sections (each) from three animals.
1 mm z-plane depth in A–C.
doi:10.1371/journal.pone.0034097.g004
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consequence of some activity by transplanted NSCs.
High levels of metalloproteinase activity adjacent to
dense cored amyloid deposits
To determine whether transplantation of MMP9-NSCs induced
greater metalloprotease activity around Ab plaques, we employed
an in situ metalloproteinase activity technique in which tissue
sections were overlaid with agar containing a substrate that is
selectively cleaved by metalloproteinases (see Methods). A previous
study that used this technique described metalloproteinase activity
adjacent to Ab plaques that were surrounded by astrocytes with
up-regulated MMP9 immunoreactivity [22]. We observed a
similar concentration of MMP activity around amyloid deposits
with no obvious increase in metalloproteinase activity levels
around Ab plaques in mice receiving MMP9-NSCs transplants. In
performing these assessments, we were impressed by the high
levels of metalloproteinase activity around Ab plaques in
transgenic mice (Fig. 7). Indeed the accuracy with which
metalloproteinase activity derived fluorescence identified Ab
plaques was similar to that of immunostaining for Ab (Fig. 7A–
C). Virtually every plaque showed intense fluorescence indicative
of high metalloproteinase activity. Robust MMP9 activity around
amyloid plaques was also observed in tetAPPsi mice in which the
expression of mutant APP, and thus the production of new Ab
deposition, had been halted for a month (Fig. 7D). MMP activity
was not observed in non-transgenic littermates (Fig. 7E) or in
sections treated with the metalloprotease inhibitor, 1,10 PNTL
(Fig. 7F). As previously reported, cells with up-regulated MMP9
were found in close proximity to Ab plaques (Fig. 7G–I) [22].
These findings indicate that there are high levels of endogenous
MMP activity associated with amyloid plaque deposits and it is
thus difficult to predict how much additional MMP activity must
be delivered to augment this natural activity, or whether higher
levels of activity would be efficacious.
Factors that affect the distribution of transplanted NSCs
In all animals examined, the primary location of engrafted
NSCs, whether expressing MMP9 with GFP or GFP alone, was
the corpus callosum and the hippocampal fissure. This pattern of
distribution is highly similar to anisotropic distributions observed
previously with small molecule infusions [26,30,36]. We therefore
repeated NSC infusions in non-transgenic mice to determine
whether the engraftment of NSCs shared spatial and temporal
properties similar to small molecules. In these experiments, NSCs
were bilaterally infused into the hippocampus and host mice were
sacrificed within fifteen minutes of the cessation of infusion. We
also infused NSCs into thalamus and the striatum to determine
Figure 5. NSC engraftment is enhanced by MMP9 overexpression. MMP9-NSC grafts (n=5) were larger than GFP-NSC grafts (n=4) in
APPswe/PS1dE9 mice (A–B). Aggregate data on the area of GFP immunoreactivity in sections with evidence of needle track penetration indicated
grafts were 82.4% larger for MMP9-NSCs compared to those expressing only GFP (C). **p,0.01.
doi:10.1371/journal.pone.0034097.g005
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Across various depths of infusion of NSCs into the hippocampus,
we consistently observed well-defined ellipsoid distributions of
GFP fluorescence in the transverse plane (Fig. 8A–B, E–F) similar
to engraftments in AD mice and previous reports of small molecule
infusion. GFP fluorescence was found distributed largely in three
structures: the corpus callosum, the velum interpositum and the
hippocampal fissure. Specifically, NSCs that were infused into the
superior aspect of the septal hippocampus yielded GFP fluores-
cence distributions throughout the corpus callosum (Fig. 8A;
n=5). NSCs targeted to the inferior aspect of the septal
hippocampus produced GFP fluorescence distributed mediolater-
ally along the velum interpositum (Fig. 8B; n=7). The velum
interpositum is a soft tissue partition between the diencephalon
and the telencephalon rather than a cavity or space [37].
Functionally, the velum interpositum forms the roof of the 3
rd
ventricle and connects the choroid plexus of this ventricle to that of
the lateral ventricle. The distribution of GFP fluorescence
extended hundreds of micrometers along the velum interpositum,
from the 3
rd ventricle to lateral regions such as above the dorsal
lateral geniculate nucleus. On the other hand, NSCs that were
infused into the thalamus (Fig. 8C; n=7) and striatum (Fig. 8D;
n=3) produced spherical distributions of GFP fluorescence that
were indicative of isotropic transport. In some instances, GFP
fluorescence was not only at the position the cells were targeted,
but also hundreds of micrometers away (Fig. 8E–F). 3D
reconstruction of serial sections of a representative corpus callosum
infusion illustrated the sheet-like spread of GFP fluorescence across
the wide, flat bundle of corpus colossal fibers (Fig. S5A). In
contrast, thalamic infusion reconstruction shows a globular spread
of GFP fluorescence (Fig. S5B). These patterns of distribution
support the idea that cells are distributed along anisotropic
Figure 6. NSC transplantation but not MMP9 overexpression was associated with reductions in Ab plaque burden in APPswe/
PS1dE9 mice. In mice with month-long engraftments, Ab plaques were reduced in the area proximal to grafts in the hemisphere receiving NSCs (A,
ipsilateral hemisphere, arrows mark the location of the graft). Across all animals, Ab plaques were reduced by 27% (B, n=9 animals). Mice receiving
MMP9-NSCs (n=5) had substantially enlarged engraftments relative to GFP-NSCs (n=4). However, the magnitude of Ab plaque reduction was similar
in both cohorts (B–C, closed squares=MMP9-NSCs, open squares=GFP-NSCs) and there was no obvious relationship between the size of the graft
and the magnitude of plaque reduction. Ab plaque burden determined from five to seven sections per animal. Engraftment size in each animal was
determined in sections containing a needle track (**, p,0.01).
doi:10.1371/journal.pone.0034097.g006
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contours of transverse engraftments, whether in mice observed
within minutes or a month after surgery, were nearly identical (Fig.
S5D). Furthermore, NSC injections in non-transgenic mice
resulted in cells that initially colonized white matter tracts (such
as the fimbria) and moved laterally within this structure, but did
not migrate into adjacent gray matter (Fig. S6).
Discussion
The properties of NSCs, namely long-term in vitro expansion
and engraftment potential [10,34], have generated significant
interest for application towards novel therapies such as cell
replacement and therapeutic delivery. In this study, we examined
NSCs as a delivery vector for secreted MMP9, a candidate AD
therapeutic. Our methods of delivery resulted in NSC engraftment
primarily white matter tracts with a location of the grafts sharing
spatial and temporal characteristics with anisotropic distributions
of small molecules. We found no evidence for significant migration
of the NSCs into surrounding gray matter, even in animals that
had survived for more than a year after transplantation. The
primary effect of expressing MMP9 in these studies was to increase
the size of the graft formed by the transplanted cells. We found no
evidence that NSC-delivered MMP9 produced any effect on
amyloid burden. Through the course of analyzing the effect of
MMP9-expressing NSCs on amyloid plaque burden in our two
models of Alzheimer-type amyloidosis, we found robust endoge-
nous metalloproteinase activity specifically around Ab plaques.
Notably, this natural response failed to clear plaques even in the
brains of the tet-APPsi mice in which expression of mutant APP
had been inhibited by doxycycline. One may interpret this to
mean that metalloproteases, even in favorable conditions in which
deposition of new amyloid has been interrupted, are not
particularly effective in clearing amyloid deposits.
Inherent therapeutic value of NSCs as anti-
amyloidogenics
One potentially interesting observation was that the area near
the engrafted NSCs, whether expressing MMP9 and GFP or GFP
alone, showed modest reductions in amyloid plaque numbers in
the APPswe/PS1dE9 model and in tetAPPsi mice. We also noted
that unmodified NSCs in culture showed the ability to degrade Ab
peptides. One interpretation of these observations is that NSCs
may possess some ability to degrade Ab and thus slow the
formation of new amyloid plaques and/or induce clearance of pre-
existing deposits. However, as mentioned above, the major effect
of expressing MMP9 was to increase the size of the graft and we
noted no linkage between graft size and amyloid load reduction.
The larger grafts appeared to contain more NSCs, and thus we
Figure 7. Localized endogenous MMP activity around Ab plaques. A thin film of DQ gelatin was digested by metalloproteases, releasing
fluorescence. This degradative activity occurred mainly around Ab plaques (A–C). The activity of metalloproteases continued despite no new
deposition of Ab for one month in tetAPPsi mice (D). MMP activity was not observed in non-transgenic littermates (E) or in sections treated with the
metalloprotease inhibitor, 1,10 PNTL (F). Antibody staining specific for mouse MMP9 indicated reactive endogenous cells (arrows) in close proximity
to Ab plaques deliver MMP9 (G–I) in APPswe/PS1dE9 mice. The images shown are representative of an analysis of at least three sections from three
animals.
doi:10.1371/journal.pone.0034097.g007
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Therefore, we are not inclined to conclude that the transplanted
NSCs had any effect on amyloid burden. We note that a previous
study by Blurton-Jones and colleagues in which NSCs were
injected into hippocampus failed to detect any local effects on
amyloid deposition [13]. Thus it is likely that the local reduction in
amyloid plaque numbers we observed may be due to some
secondary effect of transplantation.
Potential efficacy of MMP9 delivered by NSCs in amyloid
clearance
Our primary focus was to determine whether NSCs could be
used to deliver MMP9 to hippocampal regions of the brain to
catalyze reduction in amyloid burden. Despite evidence of good
expression of MMP9 by these cells in culture, this approach did
not result in significant reductions in Ab burden as compared to
the effects of transplanting NSCs expressing only GFP. Because of
the nature of negative data, we cannot definitively conclude from
our studies that NSC-mediated delivery of MMP9 will have no
benefit in humans. However, elaborating on possible reasons for
the lack of positive MMP9 effects may inform future studies on
metalloproteinase therapy. The potential reasons for lack of
efficacy mainly fall into three categories: the efficacy of
metalloproteinases towards plaque reduction, the dose and activity
of MMP9 delivered by NSCs, and finally, the proximity of NSC-
delivered MMP9 to sites of amyloid deposition.
Figure 8. Short-term engraftments demonstrate the hippocampus specifically features anisotropic transport. NSCs were surgically
infused into the brains of non-transgenic mice that were then sacrificed within fifteen minutes after cessation of infusion to observe near-immediate
transplant distribution. NSCs infused proximal to the superior aspect of the septal hippocampus (HIPPO) were mainly distributed along the transverse
plane of the corpus callosum (CC) (A). Similarly, NSCs distributed along the transverse plane of the velum interpositum (VI) when deposited more
ventrally in the inferior aspect of the hippocampus (B). Engraftments in the thalamus (THAL) (C) and striatum (D) did not preferentially distribute in
the transverse plane. 38.5% of infusions resulted in independent anisotropic (ellipsoid; arrows) and isotropic (circular; arrowheads) engraftments
distal to the target site including the hippocampal fissure (HF) (E–F). GFP fluorescence was detected directly in all panels. The images shown are
representative of an analysis of at least three tissues sections (each) from a minimum of three infusions.
doi:10.1371/journal.pone.0034097.g008
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MMP9 was that we observed high levels of metalloproteinase
activity around Ab plaques in APPswe/PS1dE9 and tetAPPsi mice
at baseline. Indeed, in situ assay for metalloproteinase activity on
tissue sections provided a very specific and robust marker for Ab
plaques. We also observed high levels of metalloproteinase activity
in tetAPPsi mice during treatment with doxycycline, indicating
that Ab deposits persist in this model despite high levels of
metalloproteinase activity in proximity to Ab plaques. Yan et al.
previously noted metalloproteinase activity in proximity to
amyloid deposits in another strain of mice that model Alzhei-
mer-type amyloidosis [22], but interpreted the finding as evidence
that MMP9 may be acting as an endogenous mechanism of
clearance. In light of studies of mice that inducibly express mutant
APP in which it has been demonstrated that Ab plaques are very
slow to spontaneously clear [6], it is difficult to imagine that
metalloproteinase can readily clear densely packed amyloid
deposits.
However, an important consideration in assessing the potential
efficacy of MMP9 in clearing amyloid deposits is that it is very
difficult to know what concentration of enzyme would be required
to clear senile plaques. In situ experiments by Yan and colleagues
suggested 70 nM (6.4 mg/mL) is sufficient to degrade Ab plaques
[22]. We estimate that conditioned media from MMP9-NSCs
contains 3 mg/mL of MMP9. Because the volume of the medium
would be much greater than the volume of the interstitial space
around the engrafted NSCs, the host tissue around NSC
engraftments may have contained MMP9 at concentrations
approaching the dose found effective in situ. However, we do not
know what fraction of the secreted proMMP9 enzyme was fully
activated, how quickly it may have been cleared, or whether it
diffused far enough from the graft site to reach the target amyloid
plaques.
NSC transplantation in therapeutic applications
One lesson learned from these studies is that there remain
fundamental questions regarding how engrafted NSCs are
ultimately distributed after transplantation. Cell migration is
clearly one determinant of graft distribution. For instance, we
have previously shown that SVC NSCs transplanted into the
lateral ventricle follow migrational cues in the rostral migrational
stream [10]. Consequently, we expected at least some NSCs to
follow directional cues in the subgranular zone, in the ventricular
walls, or respond to chemoattractants that draw astrocytes to Ab
plaques. The fact that these possibilities were not observed
suggested factors other than migration may have determined graft
localization.
To gain insight on how NSCs became distributed, we examined
NSCs immediately after injection and after long-term engraft-
ment. Unexpectedly, we found that host mice harvested only
minutes after surgery or after a month had remarkably similar
distributions of NSCs. These distributions were stereotypically on
the transverse plane and occurred mainly in the corpus callosum,
but were also observed in the hippocampal fissure and the velum
interpositum. Infusates of small molecules and macromolecules
also occur within minutes, are stereotypically in the transverse
plane, and are specific to structures such as the corpus callosum,
but not hippocampal gray matter [26,30,36]. These spatio-
temporal similarities suggest factors that determined the distribu-
tion of small molecules also influenced NSC distribution in our
transplant studies.
Interestingly, we noted that MMP9-NSC engraftments were
82.4% larger than those of GFP-NSCs. The enlargement of
engraftments due to MMP9 overexpression has also been observed
in muscle stem cell transplants [38]. These investigators interpret-
ed the larger engraftments as evidence that MMP9 expression
induces migration. Whether the larger grafts formed by MMP9-
expressing NSCs was a consequence of greater migration with the
white matter tracts or greater survival of the engrafted cells
remains to be determined. However, this finding raises the
possibility that expression of MMP9 could have utility in
therapeutic applications of NSCs as a means to enhance survival
or migration.
Finally, the morphology of the engrafted NSCs in this study was
similar to that of immature cells in the white matter tract of the
rostral migratory stream seen in our previous work [10]. Our
transplants were GFAP immunoreactive (data not shown) and it is
unlikely that these cells underwent significant differentiation [39].
Since the main criterion for their usefulness in the current study
was the expression of potentially therapeutic proteins over long
periods of time, the terminal differentiation state of the
transplanted cells was not a primary concern. In other applications
of NSC transplantation, the terminal differentiation state may well
be a major factor in efficacy.
Conclusions
In summary, we have performed a preclinical assessment of the
ease with which NSCs can be manipulated to express biologic
therapeutics, and whether such cells can form significant
engraftments in the brains of mice that exhibit Alzheimer-type
amyloid pathology. In this test case, we investigated the potential
efficacy of MMP9 in promoting the clearance of amyloid deposits.
Although we demonstrate that NSCs can indeed be easily
modified to express MMP9 and that NSCs can form significant
grafts that survive for long periods, we observed no indication that
the cells delivered a sufficient quantity of enzyme to be efficacious.
A confounding factor in the study was the high level of endogenous
MMP activity associated with amyloid plaques in these mouse
models. This result leads us to question whether raising MMP9
levels would have any practical benefit, what level of activity would
be required to be efficacious, and whether NSC-mediated delivery
could raise the levels high enough to be of benefit. Although our
results with MMP9 are not encouraging in the context of AD,
there are clearly a multitude of applications in which NSC
transplantation could be used in therapeutic applications as
delivery vehicles or as supportive replacement cells. Moreover,
the ability of these cells to survive long-term in the brains of
animals with significant disease pathology provides encourage-
ment for further development of this approach.
Supporting Information
Figure S1 NSC monolayers contain a subpopulation of
cells reactive to antibodies against the microglial
marker, Iba1. The images shown are representative of an
analysis of three experiments.
(TIF)
Figure S2 Quantification of Ab plaque burden in
APPswe/PS1dE9 mice. A defined area of consistent size
(ROI: 1.25 mm62 mm) was outlined on each hemisphere,
encompassing part of the cortex and hippocampus. 6E10
immunoreactive Ab plaques (arrowheads) within this region were
counted and compared.
(TIF)
Figure S3 Graft associated reduction of Ab plaques in
tetAPPsi mice. TetAPPsi mice on doxycycline diet to inhibit
new Ab deposition hosted MMP9-NSCs in one hemisphere for
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all but one animal (A, n=7). Across all mice, grafts were associated
with 26.1% less Ab plaques (B). The number of Ab plaques in a
graft-associated ROI of 0.25 mm60.35 mm were counted with
NIH Image J (see Methods). In follow-up experiments, GFP-NSCs
and MMP9-NSCs were bilaterally engrafted for a month. No
obvious differences were observed in this side-by-side test on the
effect of NSC derived MMP9 on pre-existing Ab deposits (C,
representative image from n=9, arrows mark the position of the
grafts).
(TIF)
Figure S4 NSCs possess an inherent capacity to degrade
Ab42 peptides. Cultured NSCs were bathed in media containing
4 mg/mL of Ab42 (n=4) before we subsequently assayed Ab42
levels in cell lysates and culture medium at 3 and 16 hours later by
ELISA. The medium was analyzed to determine whether any
peptide taken up by these cells was recycled back to medium. In all
cases we included a sample in which no cells were present in the
culture vessel to control for non-specific binding of Ab to plastic.
Note that there is significant nonspecific adherence of the peptide
to plastic, and significant re-solubilization occurs when medium is
reapplied to the vessel. Despite the unavoidable problems with
non-specific binding of Ab to culture vessels, we observed a very
significant increase in Ab levels in cell lysates after incubation with
levels quickly falling back to baseline levels (A). As Ab levels in cell
lysates declined, we did not observe a parallel increase in Ab levels
in medium above what occurs from leaching from the plastic (B
3 hrs, p,0.01; 16 hrs, p,0.01). Therefore, we conclude that NSCs
were degrading the internalized peptides. Statistical analyses were
performed as described in Materials and Methods: *,p,0.05;
**, p,0.01.
(TIF)
Figure S5 Geometric analyses of short-term NSC en-
graftments. 3D reconstruction of serial sections shows engraft-
ments form a sheet-like spread in the corpus callosum (A) and a
globular spread in the thalamus (B). To distinguish these
differences numerically, the travel distance of NSCs in the
transverse plane (x) was divided by the travel distance in the
vertical plane (y), yielding an anisotropic value, A. A is 7.36larger
in the corpus callosum compared to the thalamus (C). Similar
comparison indicates A values of the hippocampal fissure and
velum interpositum are 3.76 and 6.86, respectively, to the
thalamus (**, p,0.01, comparison to thalamus). Comparison of
the index of anisotropy of long-term engraftments in the corpus
callosum to short-term engraftments in the corpus callosum and
velum interpositum reveals near identical values (D), indicating
month-long engraftments in AD mice are anisotropic. The
anisotropic values were calculated from an analysis of a minimum
of three infusions for each structure indicated. Anisotropic values
for long-term engraftments were calculated from APPswe/PS1dE9
mice.
(TIF)
Figure S6 Engraftment in white matter results in
permanent localization of NSCs in white matter. We
infused NSCs into the fimbria, a white matter structure along the
medial edge of the hippocampus. NSCs infused into the fimbria
are positioned to migrate into the hippocampus, the thalamus or
enter the lateral ventricle. Non-transgenic mice were used to avoid
the possibility of effects specific only to AD pathology. Observation
of NSCs shortly after infusion (,15 min) revealed graft cores of
cells in close association of each other within the fimbria (A, n=6).
On the other hand, cells that were engrafted for one year migrated
within the fimbria to the walls of the lateral ventricle and near
CA3 (B–C, n=3). No cells were found in the hippocampus or the
thalamus (C, arrowheads indicate migrating cells, dashes mark
hippocampal border). Thus in our models, NSCs migrated within
white matter but did not exit to surrounding structures.
(TIF)
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